Skip to main content

Table 2 Sequence 2

From: An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)

Protocol activity

Screening*

Rando**

Day 1

Days 2–6

Day 7

Day 8

Days 9–14

Day 15

Day 16

Day 18

Day 22

Day 29 EOS

Informed consent

X

           

Enrolment

 

X

          

Remdesivir

    

X

  

X

    

TDF/3TC

  

X

X

X

       

Rich PK visit

    

X

  

X

    

Single PK sample

     

X

  

X

   

Washout period

            

Clinical review

X

 

X

XT

  

XT

X

 

XT

 

X

Vital signs

X

 

X

    

X

   

X

HBV serology

X

           

HIV serology

X

           

Malaria RDT

X

           

Safety bloods

X

   

X

X

 

X

X

 

X

 

Urinalysis

X

   

X

       

Pregnancy test

X

 

X

    

X

    

ECG

X

   

X

  

X

    

Pharmacogenomic sample

     

X

      
  1. *14-day screening period, **At least 3 days prior to drug administration, XT telephone visit, RDT rapid diagnostic test, Rando randomization
Back to article page

Trials

ISSN: 1745-6215